• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性乙型肝炎患者肝硬化发生后的自然病程:一项长期随访研究。

Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.

机构信息

Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, 199, Tung Hwa North Road, Taipei, 105, Taiwan,

出版信息

Hepatol Int. 2007 Mar;1(1):267-73. doi: 10.1007/s12072-007-5001-0.

DOI:10.1007/s12072-007-5001-0
PMID:19669348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2720722/
Abstract

PURPOSE

To elucidate the long-term natural course following the onset of cirrhosis in patients with chronic hepatitis B.

METHODS

Ninety-three patients with chronic hepatitis B who had developed cirrhosis during regular follow-up were included in this long-term follow-up study. At the time of cirrhosis detection, 30% of the patients were seropositive for hepatitis B e antigen (HBeAg) and 73% had a HBV-DNA level >10(4) copies/ml. Follow-up studies included liver biochemistry, viral markers, alpha-fetoprotein and ultrasonography every 3-6 months.

RESULTS

During a mean follow-up period of 102 +/- 60 (12-246; median 97) months, 32 patients (34.4%) experienced 55 episodes of hepatitis flare (7.0%/year), 15 (53.6%) of 28 HBeAg-positive patients seroconverted to anti-HBe (6.3%/yr) and 12 (12.9%) lost HBsAg (1.5%/year). Overall disease progression was observed in 25 (26.9%, 3.2%/year) patients: 12 (12.9%, 1.5%/year) hepatic decompensation, 21 (22.6%, 2.7%/year) hepatocellular carcinoma and 11 (11.8%, 1.4%/year) died. Multivariate analysis showed that age at onset of cirrhosis (P = 0.015) and persistent HBeAg seropositivity (P = 0.019) were the independent factors for overall disease progression.

CONCLUSIONS

These results suggest that patients with older age at onset of cirrhosis and persistent HBeAg seropositivity following the onset of cirrhosis were independent factors for the disease progression in the first 10-year after the development of cirrhosis in patients with chronic hepatitis B.

摘要

目的

阐明慢性乙型肝炎患者发生肝硬化后的长期自然病程。

方法

本长期随访研究纳入了 93 例在常规随访中发生肝硬化的慢性乙型肝炎患者。在检测到肝硬化时,30%的患者乙型肝炎 e 抗原(HBeAg)阳性,73%的患者乙型肝炎病毒脱氧核糖核酸(HBV-DNA)水平>10(4)拷贝/ml。随访研究包括每 3-6 个月进行一次肝功能检查、病毒标志物、甲胎蛋白和超声检查。

结果

在平均 102±60(12-246;中位数 97)个月的随访期间,32 例患者(34.4%)经历了 55 次肝炎发作(7.0%/年),28 例 HBeAg 阳性患者中有 15 例(53.6%)发生血清学转换(6.3%/年),12 例(12.9%)失去 HBsAg(1.5%/年)。25 例(26.9%,3.2%/年)患者出现总体疾病进展:12 例(12.9%,1.5%/年)肝失代偿,21 例(22.6%,2.7%/年)肝细胞癌,11 例(11.8%,1.4%/年)死亡。多变量分析显示,肝硬化发病时的年龄(P=0.015)和持续 HBeAg 血清阳性(P=0.019)是总体疾病进展的独立因素。

结论

这些结果表明,肝硬化发病时年龄较大和肝硬化发病后持续 HBeAg 血清阳性是慢性乙型肝炎患者发生肝硬化后 10 年内疾病进展的独立因素。

相似文献

1
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study.慢性乙型肝炎患者肝硬化发生后的自然病程:一项长期随访研究。
Hepatol Int. 2007 Mar;1(1):267-73. doi: 10.1007/s12072-007-5001-0.
2
Chronic hepatitis B virus infection in Asian countries.亚洲国家的慢性乙型肝炎病毒感染
J Gastroenterol Hepatol. 2000 Dec;15(12):1356-61. doi: 10.1046/j.1440-1746.2000.0150121356.x.
3
Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma.成人慢性乙型肝炎病毒感染的自然史,重点关注肝硬化和肝细胞癌的发生情况。
J Gastroenterol Hepatol. 2000 May;15 Suppl:E25-30. doi: 10.1046/j.1440-1746.2000.02097.x.
4
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.慢性乙型肝炎患者HBeAg自然血清学转换后的长期预后。
Hepatology. 2002 Jun;35(6):1522-7. doi: 10.1053/jhep.2002.33638.
5
Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.慢性乙型肝炎患者肝硬化发生后的自然病程:一项前瞻性研究。
Liver. 1989 Aug;9(4):235-41. doi: 10.1111/j.1600-0676.1989.tb00405.x.
6
Natural history of chronic hepatitis B REVEALed.慢性乙型肝炎的自然史被揭示。
J Gastroenterol Hepatol. 2011 Apr;26(4):628-38. doi: 10.1111/j.1440-1746.2011.06695.x.
7
[Follow-up of chronic hepatitis B carriers. Serological course and risk of reactivation].[慢性乙型肝炎携带者的随访。血清学病程及再激活风险]
Rev Esp Enferm Dig. 1996 May;88(5):335-9.
8
Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.慢性乙型肝炎合并新发肝硬化患者肝细胞癌的风险及预测因素
J Gastroenterol Hepatol. 2016 Dec;31(12):1971-1977. doi: 10.1111/jgh.13422.
9
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.慢性乙型肝炎患者长期肝硬化和肝细胞癌风险的预测模型:整合宿主和病毒特征的风险评分。
Hepatology. 2013 Aug;58(2):546-54. doi: 10.1002/hep.26385.
10
HBeAg/anti-HBe system and development of primary hepatocellular carcinoma in patients with HBsAg-positive liver cirrhosis.HBeAg/抗-HBe系统与HBsAg阳性肝硬化患者原发性肝细胞癌的发生
Hepatogastroenterology. 1983 Feb;30(1):3-5.

引用本文的文献

1
Hepatocyte Intrinsic Innate Antiviral Immunity against Hepatitis Delta Virus Infection: The Voices of Bona Fide Human Hepatocytes.肝细胞固有先天抗病毒免疫对乙型肝炎 Delta 病毒感染的作用:来自真正人类肝细胞的声音。
Viruses. 2024 May 8;16(5):740. doi: 10.3390/v16050740.
2
Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection.乙型肝炎感染高度流行地区从建模到实际临床实践的肝细胞癌风险评分
J Clin Transl Hepatol. 2023 Dec 28;11(7):1508-1519. doi: 10.14218/JCTH.2023.00087. Epub 2023 Jul 19.
3
Persistent hepatic IFN system activation in HBV-HDV infection determines viral replication dynamics and therapeutic response.HBV-HDV 感染中持续的肝 IFN 系统激活决定了病毒复制动力学和治疗反应。
JCI Insight. 2023 May 8;8(9):e162404. doi: 10.1172/jci.insight.162404.
4
Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.血清乙型肝炎病毒 DNA<2000IU/ml 的失代偿性肝硬化自然史:一项回顾性研究。
BMC Gastroenterol. 2022 Nov 9;22(1):452. doi: 10.1186/s12876-022-02541-1.
5
Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.乙型肝炎病毒感染的管理:加拿大肝病研究协会和加拿大医学微生物学与传染病协会2018年指南。
Can Liver J. 2018 Dec 25;1(4):156-217. doi: 10.3138/canlivj.2018-0008. eCollection 2018 Fall.
6
Development and Validation of a Prediction Model for Predicting the Prognosis of Postoperative Patients with Hepatocellular Carcinoma.预测肝细胞癌术后患者预后的预测模型的开发与验证
Int J Gen Med. 2022 Apr 5;15:3625-3637. doi: 10.2147/IJGM.S351265. eCollection 2022.
7
Serum Expression Level of MicroRNA-122 and Its Significance in Patients with Hepatitis B Virus Infection.血清 microRNA-122 表达水平及其在乙型肝炎病毒感染患者中的意义。
J Healthc Eng. 2022 Feb 24;2022:8430276. doi: 10.1155/2022/8430276. eCollection 2022.
8
Hepatitis B virus reactivation in rheumatoid arthritis.类风湿关节炎中的乙型肝炎病毒再激活
World J Clin Cases. 2022 Jan 7;10(1):12-22. doi: 10.12998/wjcc.v10.i1.12.
9
The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis.国家集中带量采购试点对深圳市核苷(酸)类似物使用的影响:一项中断时间序列分析。
Front Public Health. 2021 Oct 25;9:718013. doi: 10.3389/fpubh.2021.718013. eCollection 2021.
10
Guidelines for Prevention and Treatment of Chronic Hepatitis B.慢性乙型肝炎防治指南
J Clin Transl Hepatol. 2021 Oct 28;9(5):769-791. doi: 10.14218/JCTH.2021.00209. Epub 2021 Sep 28.

本文引用的文献

1
Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy.乙型肝炎病毒复制与肝脏疾病进展:抗病毒治疗的影响
Antivir Ther. 2006;11(6):669-79.
2
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.HBeAg阳性慢性肝炎的干扰素治疗可降低肝硬化和肝细胞癌的进展风险。
J Hepatol. 2007 Jan;46(1):45-52. doi: 10.1016/j.jhep.2006.08.021. Epub 2006 Oct 20.
3
Hepatitis B virus-related cirrhosis: natural history and treatment.乙型肝炎病毒相关性肝硬化:自然史与治疗
Semin Liver Dis. 2006 May;26(2):142-52. doi: 10.1055/s-2006-939752.
4
Influence of viral load and genotype in the progression of Hepatitis B-associated liver cirrhosis to hepatocellular carcinoma.病毒载量和基因型对乙型肝炎相关性肝硬化进展为肝细胞癌的影响。
Liver Int. 2005 Apr;25(2):220-5. doi: 10.1111/j.1478-3231.2005.01077.x.
5
Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications.代偿期病毒性肝硬化的自然史:一项关于主要并发症发生率及严重程度顺序的前瞻性研究
Gut. 2004 May;53(5):744-9. doi: 10.1136/gut.2003.020263.
6
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.乙型肝炎病毒流行病学、疾病负担、治疗以及当前和新出现的预防控制措施。
J Viral Hepat. 2004 Mar;11(2):97-107. doi: 10.1046/j.1365-2893.2003.00487.x.
7
Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients.持续低水平的乙肝病毒DNA可使乙肝相关肝硬化患者免于发生肝细胞癌。一项针对96例未经治疗患者的巢式病例对照研究。
Intervirology. 2003;46(2):96-104. doi: 10.1159/000069744.
8
Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy.肝炎发作与乙肝e抗原血清学转换:在抗乙肝病毒治疗中的意义
J Gastroenterol Hepatol. 2003 Mar;18(3):246-52. doi: 10.1046/j.1440-1746.2003.02976.x.
9
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients.乙型和丙型肝炎病毒感染对代偿期肝硬化自然史的影响:一项对297例患者的队列研究。
Am J Gastroenterol. 2002 Nov;97(11):2886-95. doi: 10.1111/j.1572-0241.2002.07057.x.
10
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection.慢性乙型肝炎患者伴或不伴合并感染时HBsAg自然血清学清除后的预后
Gastroenterology. 2002 Oct;123(4):1084-9. doi: 10.1053/gast.2002.36026.